Vertex Pharmaceuticals Payment for (Proceeds from) Other Investing Activity decreased by 100.0% to $0.00 in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 100.0%, from $5.30M to $0.00. Over 3 years (FY 2022 to FY 2025), Payment for (Proceeds from) Other Investing Activity shows a downward trend with a -18.9% CAGR.
Fluctuations are typically non-recurring; large values may warrant investigation into specific one-time events.
This captures miscellaneous cash flows related to investing activities that do not fit into standard categories like pro...
Standard line item in cash flow statements for miscellaneous investing adjustments.
investing_payments_for_proceeds_from_other_investing_activities| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $11.95M | $11.95M | $11.95M | $11.95M | $7.75M | $7.75M | $1.10M | $7.75M | $0.00 | $15.00M | $8.10M | $30.90M | $5.30M | $4.30M | $0.00 | $15.90M | $0.00 |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | -35.1% | +0.0% | -85.8% | +604.5% | -100.0% | — | -46.0% | +281.5% | -82.8% | -18.9% | -100.0% | — | -100.0% |
| YoY Change | — | — | — | — | -35.1% | -35.1% | -90.8% | -35.1% | -100.0% | +93.5% | +636.4% | +298.7% | — | -71.3% | -100.0% | -48.5% | -100.0% |